Amunix Pharmaceuticals, Inc.

These are still heady days for the newly in-power Labour party, not yet passed the 100-day honeymoon period and not yet the target of too much criticism, which, history tells us, will not be too far a

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Crown Will Offer $924m To Merge With Re

Vir Biotechnology, Inc. brought on a new CEO in 2023 and in 2024 it is bringing on a new therapeutic area, while announcing its second round of job cuts in less than a year. The infectious disease sp

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly The Latest Pharma Company To Sign